This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04915/identifier/chemspider/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/drug/DB04915/identifier/pubchem-compound/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04915/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB04915/identifier/drugbank/

Statements

Subject Item
n2:DB04915
rdf:type
n3:Drug
n3:description
Phenoxodiol is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors.
n3:generalReferences
# Herst PM, Petersen T, Jerram P, Baty J, Berridge MV: The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Biochem Pharmacol. 2007 Dec 3;74(11):1587-95. Epub 2007 Aug 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17904534 # Choueiri TK, Wesolowski R, Mekhail TM: Phenoxodiol: isoflavone analog with antineoplastic activity. Curr Oncol Rep. 2006 Mar;8(2):104-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16507219 # Mor G, Fu HH, Alvero AB: Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr Opin Investig Drugs. 2006 Jun;7(6):542-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16784025 # Klein R, Brown D, Turnley AM: Phenoxodiol protects against Cisplatin induced neurite toxicity in a PC-12 cell model. BMC Neurosci. 2007 Aug 1;8:61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17672914
n3:group
investigational
n3:indication
Intended for the treatment of various forms of cancer.
owl:sameAs
n9:DB04915
dcterms:title
Phenoxodiol
adms:identifier
n6:219100 n10:15121904 n11:189918 n12:DB04915
n3:mechanismOfAction
The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Results from one study (PMID: 17904534) indicate that plasma membrane electron transport (PMET) may be a primary target for phenoxodiol in tumour cells and in activated T cells.
n3:synonym
NV06 Idronoxil 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol Dehydroequol NV-06 Haginin E
n3:IUPAC-Name
n4:271B5ED6-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5EDC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5EDB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5ED8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5ED9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5EDA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5ED4-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5ED2-363D-11E5-9242-09173F13E4C5 n4:271B5ED5-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5ED3-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5EE2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5EE3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5EDD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5EDE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5EE0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5EDF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5EE1-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
81267-65-4
n3:category
n3:Bioavailability
n4:271B5EE8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5EEA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5EEB-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5EE7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5EE6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5EE9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5ED7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5EE4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5EE5-363D-11E5-9242-09173F13E4C5